The companies agreed Transgene would be paid a fixed total amount, with installments made at specified times over the life of the contract to produce the Innogenetics vaccine. The exact amount payable was not specified.
The vaccine, developed by Transgene under a previous service agreement with Innogenetics, uses modified vaccinia ankara (MVA) vector technology to express polyepitopes of the hepatitis B virus. Production of the vaccine will take place in Transgene’s manufacturing unit located near Strasbourg, using its proprietary manufacturing process and will include generation of a clinical batch and related pharmaceutical intermediates.
Philippe Archinard, CEO of Transgene said of the deal; “It is a recognition of our leading expertise in the engineering and manufacturing of viral recombinant vaccines. This agreement also enables us to deliver on our promises to better leverage our assets, including our bio-manufacturing capacities.”
Transgene currently has three compounds in phase II trials and one compound in phase I study.